Develops oncology and hematology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies.
Aptevo Therapeutics Inc. is a dynamic clinical-stage biotechnology company focused on advancing innovative immunotherapeutic candidates tailored for the treatment of various cancer types within the United States. Founded in 2016 and headquartered in Seattle, Washington, Aptevo Therapeutics is committed to pioneering novel therapies that harness the power of the immune system to combat cancer. At the forefront of its pipeline is APVO436, a bispecific T-cell engaging antibody currently undergoing Phase 1b clinical trials targeting acute myelogenous leukemia and myelodysplastic syndrome.
In addition to APVO436, Aptevo Therapeutics is actively developing a range of promising preclinical candidates. These include ALG.APV-527, an investigational bispecific ADAPTIR candidate designed to target 4-1BB (CD137) and 5T4, a tumor antigen expressed across multiple cancer types. Furthermore, APVO603 represents a dual agonist bispecific antibody aimed at targeting 4-1BB and OX40, highlighting the company's innovative approach to enhancing immune responses against cancer.
Aptevo Therapeutics' robust pipeline also features APVO442, a bispecific candidate leveraging the ADAPTIR-FLEX platform technology to improve drug biodistribution specifically to PSMA-positive tumors for the treatment of prostate cancer. Through strategic collaborations, such as the partnership with Alligator Bioscience AB to develop ALG.APV-527, Aptevo Therapeutics continues to advance its mission of transforming cancer treatment through cutting-edge immunotherapy solutions.